摘要
目的 探讨乳腺癌组织分型、分级等临床病理特征和ER、PR与p16、p2 1WAF1/CIP1和CyclinD1蛋白表达的关系。方法 进行免疫组化染色法检测 5 0例术前均未作放化疗的乳腺癌组织中p16、p2 1WAF/CIP1和CyclinD1蛋白的表达。结果 p16蛋白表达阳性率为 5 8 0 % (2 9/ 5 0 ) ,在浸润性导管癌Ⅱ级与Ⅲ级之间p16蛋白表达有显著性差异 (P <0 0 5 ) ,阳性率分别为 75 0 %、41 7%。p16、p2 1CyclinD1蛋白表达 ,p2 1蛋白表达阳性率为 30 0 % (15 / 5 0 ) ,p2 1表达阳性者与阴性者相比 ,淋巴结转移率有显著性差异 (P <0 0 5 )。CyclinD1蛋白表达阳性率为 32 0 % (16 / 5 0 )。与临床病理特征、ER和PR未见相关 (P >0 0 5 )。结论 p16和p2 1蛋白可作为判断肿瘤生物学行为的参数。
Objective To investigate the clinico pathological features of breast carcinoma and its correlation with the expression of p16, p21 WAF1/CIP1 and cylcin D1 proteins. Methods Immunohistochemical staining was used to test the expression of p16, p21 WAF1/CIP1 and cyclin D1 proteins in breast cancer tissues. All of these 50 female patients had not received radiotherapy nor chemotherapy.Results The positive expression of p16 was demonstrated in 29 of 50 (58 0 %). The positive rates in grade Ⅱ and grade Ⅲ infiltrating duct carcinoma were 75 0 % and 41 7 % respectively ( P <0 05), but there was no significant relation with other clinico pathological features and ER and PR. There was a remarkable difference of positive or negative expressions of p16 in carcinoma with lymph nodes involvement or not. There was no statistical significance between expression of p21 WAF1/CIP1 and any other parameters. The positive expression of cyclin D1 was seen in 16 of 50 (32 0 %) and there was no significant association with other parameters.Conclusion p16 and p21 WAF1/CIP1 may be useful in estimating the biological behaviours of breast carcinoma.$$$$
出处
《肿瘤》
CAS
CSCD
北大核心
2001年第3期205-207,F003,共4页
Tumor
